TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection

908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago.

MarketBeat • Aug 18, 2026

908 Devices Eyes Growth in Handheld Drug and Chemical Detection Market

908 Devices NASDAQ: MASS is sharpening its focus on handheld chemical and drug detection systems for public safety, defense and law enforcement following the divestiture of its bioprocessing and biopharma business line, executives said during a Canaccord Genuity discussion.

MarketBeat • Aug 15, 2026

908 Devices Q2: Another Solid Report

908 Devices delivered another revenue beat in Q2, as device sales continued to shine. Q2 revenues grew 23% year-over-year to $16.07 million, with product revenue up nearly 35.5% and the installed base expanding 23%. Management raised 2026 revenue guidance to $68–$70 million, implying 21–25% growth, while operating and net losses narrowed.

Seeking Alpha • Aug 13, 2026

908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that CEO and Co-founder Kevin J. Knopp and CFO Joe Griffith will present and host investor meetings at the 17th Annual Midwest IDEAS Conference on Wednesday, August 26, 2026. The Company presentation is scheduled to begin at 9:55 a.m. CT / 10:55 a.m. ET. The presentation is.

Business Wire • Aug 12, 2026

908 Devices: Mission Critical Devices Drive Growth

908 Devices is rated BUY after a 2Q26 earnings beat, strong revenue growth, and a 97% YTD share price gain. MASS benefits from robust demand for chemical detection devices, driven by law enforcement, defense, and volatile geopolitical conditions. Recurring revenue from NIRLab and product upgrades like VipIR underpin stable growth; management raised FY26 revenue guidance to $68–$70M.

Seeking Alpha • Aug 12, 2026

908 Devices Q2 Earnings Call Highlights

908 Devices NASDAQ: MASS reported second-quarter revenue growth of 23% as demand from U.S. state and local government customers, FTIR product shipments and its recently acquired NIRLab platform supported results. The company also raised the low end of its full-year revenue outlook while continuing to exclude potential revenue from the U.S. military's AVCAD program from its core guidance.

MarketBeat • Aug 11, 2026

908 Devices Inc. (MASS) Q2 2026 Earnings Call Transcript

908 Devices Inc. (MASS) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 11, 2026

908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety, and defense tech applications, today reported financial results for the quarter ended June 30, 2026. “We delivered another strong quarter, growing revenue 23% year-over-year, while narrowing our Adjusted EBITDA loss by more than half compared to a year ago,” said Kevin J. Knopp, CEO and Co-founder. “Our momentum.

Business Wire • Aug 11, 2026

908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates

908 Devices Inc. (MASS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.18 per share a year ago.

Zacks Investment Research • Aug 11, 2026

908 Devices Inc. (MASS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

908 Devices (MASS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Aug 4, 2026